 RESEARCH TRIANGLE PARK, N.C., Sept. 15, 2021 GLOBE NEWSWIRE -- BioCryst Pharmaceuticals, Inc. Nasdaq: BCRX today announced that the United Kingdoms UK National Institute for Health and Care Excellence NICE has recommended ORLADEYO berotralstat for preventing recurrent attacks of hereditary angioedema HAE in eligible patients 12 years and older if they have at least two attacks per month. With this recommendation, HAE patients in England, Wales and Northern Ireland will have access to the first oral, once-daily therapy for routine prevention of recurrent HAE attacks. 